Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-Type natriuretic peptide in Patients with chronic heart failure

Wayne L. Miller, Mary A. Phelps, Christina M. Wood, Ute Schellenberger, Anh Van Le, Regis Perichon, Allan S Jaffe

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Background-Multiple B-type natriuretic peptide (BNP) fragments circulate in patients with heart failure (HF) but the types and relative quantities, particularly in relation to bioactive BNP 1-32, remain poorly defined. The purpose of the study was to relate clinically available BNP values with quantitative information on the concentration of pre-secretion and post-processed fragments of BNP detected by mass spectrometry. Methods and Results-Seventy Class I-IV patients were prospectively enrolled with blood drawn into tubes containing a preservative to protect against BNP degradation. Samples were analyzed by quantitative mass spectrometry (MS) immunoassay for intact BNP 1-32 and its fragments. Clinical BNP 1-2 was measured by standard clinical laboratory methods. ProBNP 1-108, corin, and clinically measured BNP levels were elevated, but MS BNP 1-32 levels were low and differed from clinical BNP (P=0.01). Intact MS BNP 1-32 correlated modestly with clinical BNP (r=0.46, P<0.001). MS BNP fragments 3-32, 4-32, and 5-32 demonstrated the best associations with clinical BNP; fragment 5-32 with a correlation coefficient of r=0.81 (P<0.001). Conclusions-ProBNP 1-108 is measured by clinical BNP assays and contributes to the cumulative results of the BNP assay. However, the observation that clinically measured BNP correlates best with MS degradation fragments and relatively poorly with MS BNP 1-32 suggests that a significant component of circulating clinical BNP is composed of such fragments that are known to demonstrate little biological activity. There appear to be multiple pathways involved in the dysregulation of proBNP in HF, and both the processing of proBNP and the downstream degradation to BNP 1-32 appear to be critical.

Original languageEnglish (US)
Pages (from-to)355-360
Number of pages6
JournalCirculation: Heart Failure
Volume4
Issue number3
DOIs
StatePublished - May 2011

Fingerprint

Brain Natriuretic Peptide
Mass Spectrometry
Heart Failure
Peptide Fragments

Keywords

  • BNP 1-32
  • BNP fragments
  • Cardiomyopathy
  • Corin
  • Heart failure
  • Mass spectrometry immunoassay
  • Natriuretic peptides
  • ProBNP

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-Type natriuretic peptide in Patients with chronic heart failure. / Miller, Wayne L.; Phelps, Mary A.; Wood, Christina M.; Schellenberger, Ute; Van Le, Anh; Perichon, Regis; Jaffe, Allan S.

In: Circulation: Heart Failure, Vol. 4, No. 3, 05.2011, p. 355-360.

Research output: Contribution to journalArticle

Miller, Wayne L. ; Phelps, Mary A. ; Wood, Christina M. ; Schellenberger, Ute ; Van Le, Anh ; Perichon, Regis ; Jaffe, Allan S. / Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-Type natriuretic peptide in Patients with chronic heart failure. In: Circulation: Heart Failure. 2011 ; Vol. 4, No. 3. pp. 355-360.
@article{2852fe8cca8f469db8f2aadcec297521,
title = "Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-Type natriuretic peptide in Patients with chronic heart failure",
abstract = "Background-Multiple B-type natriuretic peptide (BNP) fragments circulate in patients with heart failure (HF) but the types and relative quantities, particularly in relation to bioactive BNP 1-32, remain poorly defined. The purpose of the study was to relate clinically available BNP values with quantitative information on the concentration of pre-secretion and post-processed fragments of BNP detected by mass spectrometry. Methods and Results-Seventy Class I-IV patients were prospectively enrolled with blood drawn into tubes containing a preservative to protect against BNP degradation. Samples were analyzed by quantitative mass spectrometry (MS) immunoassay for intact BNP 1-32 and its fragments. Clinical BNP 1-2 was measured by standard clinical laboratory methods. ProBNP 1-108, corin, and clinically measured BNP levels were elevated, but MS BNP 1-32 levels were low and differed from clinical BNP (P=0.01). Intact MS BNP 1-32 correlated modestly with clinical BNP (r=0.46, P<0.001). MS BNP fragments 3-32, 4-32, and 5-32 demonstrated the best associations with clinical BNP; fragment 5-32 with a correlation coefficient of r=0.81 (P<0.001). Conclusions-ProBNP 1-108 is measured by clinical BNP assays and contributes to the cumulative results of the BNP assay. However, the observation that clinically measured BNP correlates best with MS degradation fragments and relatively poorly with MS BNP 1-32 suggests that a significant component of circulating clinical BNP is composed of such fragments that are known to demonstrate little biological activity. There appear to be multiple pathways involved in the dysregulation of proBNP in HF, and both the processing of proBNP and the downstream degradation to BNP 1-32 appear to be critical.",
keywords = "BNP 1-32, BNP fragments, Cardiomyopathy, Corin, Heart failure, Mass spectrometry immunoassay, Natriuretic peptides, ProBNP",
author = "Miller, {Wayne L.} and Phelps, {Mary A.} and Wood, {Christina M.} and Ute Schellenberger and {Van Le}, Anh and Regis Perichon and Jaffe, {Allan S}",
year = "2011",
month = "5",
doi = "10.1161/CIRCHEARTFAILURE.110.960260",
language = "English (US)",
volume = "4",
pages = "355--360",
journal = "Circulation: Heart Failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-Type natriuretic peptide in Patients with chronic heart failure

AU - Miller, Wayne L.

AU - Phelps, Mary A.

AU - Wood, Christina M.

AU - Schellenberger, Ute

AU - Van Le, Anh

AU - Perichon, Regis

AU - Jaffe, Allan S

PY - 2011/5

Y1 - 2011/5

N2 - Background-Multiple B-type natriuretic peptide (BNP) fragments circulate in patients with heart failure (HF) but the types and relative quantities, particularly in relation to bioactive BNP 1-32, remain poorly defined. The purpose of the study was to relate clinically available BNP values with quantitative information on the concentration of pre-secretion and post-processed fragments of BNP detected by mass spectrometry. Methods and Results-Seventy Class I-IV patients were prospectively enrolled with blood drawn into tubes containing a preservative to protect against BNP degradation. Samples were analyzed by quantitative mass spectrometry (MS) immunoassay for intact BNP 1-32 and its fragments. Clinical BNP 1-2 was measured by standard clinical laboratory methods. ProBNP 1-108, corin, and clinically measured BNP levels were elevated, but MS BNP 1-32 levels were low and differed from clinical BNP (P=0.01). Intact MS BNP 1-32 correlated modestly with clinical BNP (r=0.46, P<0.001). MS BNP fragments 3-32, 4-32, and 5-32 demonstrated the best associations with clinical BNP; fragment 5-32 with a correlation coefficient of r=0.81 (P<0.001). Conclusions-ProBNP 1-108 is measured by clinical BNP assays and contributes to the cumulative results of the BNP assay. However, the observation that clinically measured BNP correlates best with MS degradation fragments and relatively poorly with MS BNP 1-32 suggests that a significant component of circulating clinical BNP is composed of such fragments that are known to demonstrate little biological activity. There appear to be multiple pathways involved in the dysregulation of proBNP in HF, and both the processing of proBNP and the downstream degradation to BNP 1-32 appear to be critical.

AB - Background-Multiple B-type natriuretic peptide (BNP) fragments circulate in patients with heart failure (HF) but the types and relative quantities, particularly in relation to bioactive BNP 1-32, remain poorly defined. The purpose of the study was to relate clinically available BNP values with quantitative information on the concentration of pre-secretion and post-processed fragments of BNP detected by mass spectrometry. Methods and Results-Seventy Class I-IV patients were prospectively enrolled with blood drawn into tubes containing a preservative to protect against BNP degradation. Samples were analyzed by quantitative mass spectrometry (MS) immunoassay for intact BNP 1-32 and its fragments. Clinical BNP 1-2 was measured by standard clinical laboratory methods. ProBNP 1-108, corin, and clinically measured BNP levels were elevated, but MS BNP 1-32 levels were low and differed from clinical BNP (P=0.01). Intact MS BNP 1-32 correlated modestly with clinical BNP (r=0.46, P<0.001). MS BNP fragments 3-32, 4-32, and 5-32 demonstrated the best associations with clinical BNP; fragment 5-32 with a correlation coefficient of r=0.81 (P<0.001). Conclusions-ProBNP 1-108 is measured by clinical BNP assays and contributes to the cumulative results of the BNP assay. However, the observation that clinically measured BNP correlates best with MS degradation fragments and relatively poorly with MS BNP 1-32 suggests that a significant component of circulating clinical BNP is composed of such fragments that are known to demonstrate little biological activity. There appear to be multiple pathways involved in the dysregulation of proBNP in HF, and both the processing of proBNP and the downstream degradation to BNP 1-32 appear to be critical.

KW - BNP 1-32

KW - BNP fragments

KW - Cardiomyopathy

KW - Corin

KW - Heart failure

KW - Mass spectrometry immunoassay

KW - Natriuretic peptides

KW - ProBNP

UR - http://www.scopus.com/inward/record.url?scp=79960584348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960584348&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.110.960260

DO - 10.1161/CIRCHEARTFAILURE.110.960260

M3 - Article

C2 - 21292992

AN - SCOPUS:79960584348

VL - 4

SP - 355

EP - 360

JO - Circulation: Heart Failure

JF - Circulation: Heart Failure

SN - 1941-3297

IS - 3

ER -